On February 22, 2011, the U. S. Supreme Court held that a federal law expressly preempts all state-law products liability suits challenging the design of widely ...
Feb 22, 2011 ... On February 22, 2011, the U.S. Supreme Court decided Bruesewitz v. Wyeth LLC , No. 09-152, holding that the National Childhood Vaccine ...
Bruesewitz v. Wyeth's Impact on the Vaccine Safety Debate. By Erin C. Fuse Brown1 & Jalayne J. Arias2, Public Health Law and Policy Program at Sandra Day ...
Apr 22, 2010 ... sialic acid in all invasive meningococcal groups other than ..... er-membrane vesicle.52 Furthermore, Wyeth in- ..... Nedelec J, Boucraut J, Garnier JM, Ber- .... Bernfield L, Barniak V, et. 48. al. Vaccine potential of the Neisseria.
Claude Granier .... All selected peptides had a higher-than-expected frequency of positive residues .... Indeed, anti-C2 Abs from different patients are mostly encoded by the DP-5 V gene, which is the case for Bo2C11. ... Supported by a grant from Wyeth Genetics Institute. ... Jacquemin MG, Desqueper BG, Benhida A , et al.
Jun 1, 2008 ... In contrast, compared with controls, 2-h glucose (135 ± 23 vs.120 ± 25 mg/dl; P = 0.01) and fasting ...... Consistent with our findings, Sheu et al.
Denise Garnier. González-Uribe .... Fabián Pablo Salvador Pelleriti et al. v. Instituto ...... The U.S. pharmaceutical company Wyeth is the owner of the trademark ...
Fifteen years later, Fournier et al. ... However, through different molecular studies, Brisse et al. ... alone or combined with 4 μg of tazobactam (Wyeth-Lederle)/ml; cephalothin (Lilly, ..... Granier, S. A., V. Leflon-Guibout, F. W. Goldstein, and M. H. ...
Aug 22, 2005 ... Gemtuzumab ozogamicin (GO) (Mylotarg®; Wyeth Pharmaceuticals, Philadelphia , PA) is a ... At study entry, all patients had CD33‐positive AML in untreated first recurrence, .... CRp group, and 4.2 months for patients who did not enter remission (CR or CRp vs. ..... 6 Thomas X, Fenaux P, Dombret H, et al.